<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35016">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02650713</url>
  </required_header>
  <id_info>
    <org_study_id>WP29945</org_study_id>
    <secondary_id>RG7802</secondary_id>
    <secondary_id>2015-003771-30</secondary_id>
    <nct_id>NCT02650713</nct_id>
  </id_info>
  <brief_title>A Study of the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen (CEA)-Positive Solid Tumors</brief_title>
  <official_title>AN OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6958688 IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA-POSITIVE SOLID TUMORS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This is an open-label, multi-center, dose escalation and expansion Phase IB clinical study
      of RO6958688 in combination with atezolizumab.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Area Under the Concentration Curve (AUC)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Volume of Distribution at Steady State (Vss)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Minimum Serum Concentration (Cmin)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Maximum serum concentration (Cmax)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Time to Cmax (Tmax)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Clearance (CL)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Assessment: Half-life (t1/2)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Overall Response Rate (ORR)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 2.5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Advanced/Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>RO6958688+Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each treatment cycle will be 21 days in duration and will consist of IV infusions of RO6958688 given weekly (QW) (+/- 1 day) in combination with atezolizumab given every 3 weeks (Q3W) (+/- 2 days). Participants will receive atezolizumab (1200 mg fixed dose) IV on Day 1 of each cycle, followed by RO6958688 at least one hour later, given IV on Day 1, Day 8 and Day 15 of each cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab [TECENTRIQ]</intervention_name>
    <description>Atezolizumab will be administered 1200 mg fixed dose IV on Day 1 of each cycle.</description>
    <arm_group_label>RO6958688+Atezolizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO6958688</intervention_name>
    <description>RO6958688 will be administered by IV infusion at least one hour after the end of infusion of atezolizumab, on Day 1, Day 8 and Day 15 of each cycle.</description>
    <arm_group_label>RO6958688+Atezolizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed locally advanced and/or metastatic solid tumor in participants who have
             progressed on a standard therapy, are intolerant to standard therapy, and/or are
             non-amenable to standard therapy

          -  Life expectancy (in the opinion of the investigator) of &gt;= 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1

          -  All acute toxic effects of any prior radiotherapy, chemotherapy, or surgical
             procedure must have resolved to Grade &lt;= 1 or returned to baseline, except alopecia
             (any grade) and Grade 2 peripheral neuropathy

          -  Adequate hematological, liver, and renal functions

          -  Negative serum pregnancy test within 7 days prior to study treatment in premenopausal
             women and women &lt;= 2 years after start of menopause

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive methods that result in a failure rate
             of &lt; 1% per year during the treatment period and for at least 90 days after the last
             dose of study drugs

          -  Locally confirmed CEA expression in tumor tissue

        Exclusion Criteria:

          -  Active or untreated central nervous system (CNS) metastases as determined by computed
             tomography (CT) or magnetic resonance imaging (MRI) evaluation during screening and
             prior radiographic assessments

          -  Spinal cord compression not definitively treated with surgery and/or radiation or
             previously diagnosed and treated spinal cord compression without evidence that
             disease has been clinically stable for &gt;= 2 weeks prior to enrollment

          -  Leptomeningeal disease

          -  Malignancies other than non-small-cell lung cancer (NSCLC) within 5 years prior to
             enrollment, with the exception of those with a negligible risk of metastasis or death
             and treated with expected curative outcome (such as adequately treated carcinoma in
             situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer
             treated surgically with curative intent, ductal carcinoma in situ treated surgically
             with curative intent)

          -  Significant, uncontrolled concomitant diseases which could affect compliance with the
             protocol or interpretation of results, including diabetes mellitus, pulmonary
             disorders, and known autoimmune diseases

          -  Uncontrolled hypertension (systolic blood pressure (BP) &gt; 150 mmHg and/or diastolic
             BP &gt; 100 mmHg), unstable angina, congestive heart failure (CHF) of any New York Heart
             Association (NYHA) classification (Class II or greater), serious cardiac arrhythmia
             requiring treatment (exceptions: atrial fibrillation, paroxysmal supraventricular
             tachycardia), history of myocardial infarction within 6 months of enrollment

          -  Administration of a live, attenuated vaccine within 28 days before Day 1 or
             anticipation that such a live attenuated vaccine will be required during the study

          -  Known HIV

          -  Active Hepatitis B (HBV) or Hepatitis C (HCV) infection (required at screening)

          -  Severe infections within 28 days prior to Day 1, including, but not limited to
             hospitalization for complications of infection, bacteremia, or severe pneumonia or
             active tuberculosis

          -  Received oral or intravenous (IV) antibiotics within 14 days prior to Day 1 (Patients
             receiving prophylactic antibiotics (e.g., for prevention of a urinary tract
             infection) are eligible)

          -  Any other diseases, metabolic dysfunction, physical examination finding, or clinical
             laboratory finding giving reasonable suspicion of a disease or condition that would
             contraindicate the use of an investigational drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Reference Study ID Number: WP29945 www.roche.com/about_roche/roche_worldwide.htm</last_name>
    <phone>888-662-6728 (U.S. and Canada)</phone>
    <email>global.rochegenentechtrials@roche.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10017</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1066 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 1, 2016</lastchanged_date>
  <firstreceived_date>January 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
